Another term for CSU is chronic idiopathic urticaria (CIU).
Chronic hives last for more than six weeks.
Ligelizumab is in development at the Swiss multinational drug company, Novartis Pharmaceuticals, as a treatment for CSU.
Guido Mieth / Getty Images
It is still undergoing Phase 3 clinical trials.
Notably, CSU is not triggered by an allergic reaction.
Side Effects
Ligelizumab is generally well tolerated by patients with CSU.
Is Ligelizumab Available?
Because ligelizumab is still in Phase 3 clinical trials, it isn’t available yet.
Is Ligelizumab FDA Approved?
As of early October 2022, ligelizumab hasn’t been approved by the FDA.
A Word From Verywell
Living with CSU disrupts quality of life and makes it hard to sleep.
Frequently Asked Questions
Ligelizumab is a biologic drug.
It’s a humanized monoclonal antibody that’s derived from non-human living organisms.
Ligelizumab is an injectable drug that is administered subcutaneously via injection.
Ligelizumab is not approved by the FDA yet and is not currently available.
Final research data will be made publicly available by the drug’s manufacturer, Novartis, in late 2022.
2022;77(7):2175-2184. doi:10.1111/all.15175
NIH.
2021;10(3).
September 2024:S1323893024001072.
2022;12(2).
doi:10.1002/clt2.12121
PharmaTimes.US breakthrough designation for ligelizumab in chronic spontaneous urticaria.
U.S. Food and Drug Administration.Frequently asked questions: breakthrough therapies.
